期刊
TOXICOLOGY
卷 324, 期 -, 页码 1-9出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.tox.2014.07.001
关键词
Autophagy; Neurotoxin; LRRK2; Parkinson's disease; Cell death
资金
- ISCIII [CA00/01506]
- Instituto Biodonostia
- Miguel Servet contract (ISCIII, Ministerio de Economia y Competitividad, Spain)
- Ministerio de Economia y Competitividad, Spain [PI11/00040, PI12/02280]
- CIBERNED [CB06/05/0041]
- Consejeria, Economia, Comercio e Innovacion
- Gobierno de Extremadura [GRU10054]
- Association Francaise contre les Myopathies [12642]
- Spanish Ministry of Health [FIS PS09-00660]
- Ilundain Foundation
- Isabel Gemio Foundation
- Diputacion Foral de Gipuzkoa [DFG09/001]
- SAIOTEK [SAIO12-PE12BN008]
Parkinson's disease (PD) is a neurodegenerative disorder of unknown etiology. It is considered as a multifactorial disease dependent on environmental and genetic factors. Deregulation in cell degradation has been related with a significant increase in cell damage, becoming a target for studies on the PD etiology. In the present study, we have characterized the parkinsonian toxin 1-methyl-4-phenylpyridinium ion (MPP+)-induced damage in fibroblasts from Parkinson's patients with the mutation G2019S in leucine-rich repeat kinase 2 protein (LRRK2) and control individuals without this mutation. The results reveal that MPP+ induces mTOR-dependent autophagy in fibroblasts. Moreover, the effects of caspase-dependent cell death to MPP+ were higher in cells with the G2019S LRRK2 mutation, which showed basal levels of autophagy due to the G2019S LERK2 mutation (mTOR-independent). The inhibition of autophagy by 3-methyladenine (3-MA) treatment reduces these sensitivity differences between both cell types, however, the inhibition of autophagosome lysosome fusion by bafilomycin A1 (Baf A1) increases these differences. This data confirm the importance of the combination of genetic and environmental factors in the PD etiology. Thereby, the sensitivity to the same damage may be different in function of a genetic predisposition, reason why individuals with certain mutations can develop some early-onset diseases, such as individuals with G2019S LRRK2 mutation and PD. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据